In
its earliest stage, an Alzheimer's diagnosis can
be extremely difficult. This promising diagnostic
gives a physician the ability to:
-
Confidently
Diagnose Alzheimer's
-
Predict the Effectiveness of Current Medical Treatments
-
Encourage and Reduce the Fear of Early Diagnosis
-
Facilitate Earlier Treatments to Delay Memory
Loss
The
European patent is an examined document, and is
enforceable as a patent and is effective as European
Patent No. 1254251 when it's published in the 15
August 2007 European Patent Bulletin. Samaritan
is planning to take the appropriate steps to fulfill
patent registration requirements in the following
European countries: Austria, Belgium, Switzerland,
Liechtenstein, Germany, Spain, France, Great Britain,
Ireland, Italy, the Netherlands, and Sweden.
Samaritan
has exclusively licensed this patent from Georgetown
University.
See
peer reviewed journal publications: http://www.samaritanpharma.com/publications_and_patents.asp
Samaritan
Pharmaceuticals: ``Transforming Today's Science Into
Tomorrow's Cures...''
Samaritan Pharmaceuticals is a life science company
focused on commercializing innovative drugs to relieve
the suffering of patients with Alzheimer's, cancer,
heart disease, and infectious disease. Samaritan's
business strategy is to partner its later stage drugs
after Phase II (proof of concept) human studies and
has executed its first partnership for its PII, HIV
drug SP-01A, with Pharmaplaz, Ireland. The FDA has
authorized an investigational new drug (IND) # and
a Phase I for its Alzheimer's drug Caprospinol and
Samaritan has several other drugs it is advancing
to enter (IND) status. In addition, Samaritan's sales
arm has acquired the marketing and sales rights to
sell ten revenue-generating products in Greece and
various Eastern European countries.
Website:
http://www.samaritanpharma.com.
Please register so we can notify you of upcoming conference
calls, news and events.
Disclaimer:
The company disclaims any information that is created
by an outside party and endorses only information
that is communicated by its press releases, filings,
and Website. This news release contains forward-looking
statements that reflect management's current beliefs
about the potential for its drug candidates, science,
and technology. However, as with any biopharmaceutical
under development, there are significant risks and
uncertainties in the process of development and regulatory
review. There are no guarantees that products will
prove to be commercially successful. For additional
information about the factors that affect the company's
business, please read the company's latest Form 10-K
filed April 13, 2007. The company undertakes no duty
to update forward-looking statements.
Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210
Samaritan Pharmaceuticals, Inc.
Kristi Eads
702-735-7001
